Future development of small molecules that selectively target the interaction between MAP 1B-LC1 and hnRNP K could be useful for inhibiting the metastasis of lung cancer cells, which will accelerate the development of novel targets for lung cancer treatment. This evidence concerns the gene HNRNPK and lung cancer.